322 related articles for article (PubMed ID: 25609248)
1. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies.
Wong AL; Soo RA; Tan DS; Lee SC; Lim JS; Marban PC; Kong LR; Lee YJ; Wang LZ; Thuya WL; Soong R; Yee MQ; Chin TM; Cordero MT; Asuncion BR; Pang B; Pervaiz S; Hirpara JL; Sinha A; Xu WW; Yuasa M; Tsunoda T; Motoyama M; Yamauchi T; Goh BC
Ann Oncol; 2015 May; 26(5):998-1005. PubMed ID: 25609248
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies.
Ogura M; Uchida T; Terui Y; Hayakawa F; Kobayashi Y; Taniwaki M; Takamatsu Y; Naoe T; Tobinai K; Munakata W; Yamauchi T; Kageyama A; Yuasa M; Motoyama M; Tsunoda T; Hatake K
Cancer Sci; 2015 Jul; 106(7):896-901. PubMed ID: 25912076
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.
Jänne PA; Boss DS; Camidge DR; Britten CD; Engelman JA; Garon EB; Guo F; Wong S; Liang J; Letrent S; Millham R; Taylor I; Eckhardt SG; Schellens JH
Clin Cancer Res; 2011 Mar; 17(5):1131-9. PubMed ID: 21220471
[TBL] [Abstract][Full Text] [Related]
4. Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma.
Yoo C; Kang J; Lim HY; Kim JH; Lee MA; Lee KH; Kim TY; Ryoo BY
Cancer Res Treat; 2019 Apr; 51(2):510-518. PubMed ID: 29898591
[TBL] [Abstract][Full Text] [Related]
5. Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors.
Bendell JC; Hong DS; Burris HA; Naing A; Jones SF; Falchook G; Bricmont P; Elekes A; Rock EP; Kurzrock R
Cancer Chemother Pharmacol; 2014 Jul; 74(1):125-30. PubMed ID: 24819685
[TBL] [Abstract][Full Text] [Related]
6. Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors.
Oh DY; Lee SH; Han SW; Kim MJ; Kim TM; Kim TY; Heo DS; Yuasa M; Yanagihara Y; Bang YJ
Cancer Res Treat; 2015 Oct; 47(4):607-15. PubMed ID: 25715763
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations.
Nishio M; Murakami H; Ohe Y; Hida T; Sakai H; Kasahara K; Imamura F; Baba T; Kubota K; Hosomi Y; Shimokawa T; Hayashi H; Miyadera K; Tamura T
Invest New Drugs; 2019 Dec; 37(6):1207-1217. PubMed ID: 30790152
[TBL] [Abstract][Full Text] [Related]
8. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
[TBL] [Abstract][Full Text] [Related]
9. A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.
Angevin E; Spitaleri G; Rodon J; Dotti K; Isambert N; Salvagni S; Moreno V; Assadourian S; Gomez C; Harnois M; Hollebecque A; Azaro A; Hervieu A; Rihawi K; De Marinis F
Eur J Cancer; 2017 Dec; 87():131-139. PubMed ID: 29145039
[TBL] [Abstract][Full Text] [Related]
10. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.
Shapiro GI; Rodon J; Bedell C; Kwak EL; Baselga J; Braña I; Pandya SS; Scheffold C; Laird AD; Nguyen LT; Xu Y; Egile C; Edelman G
Clin Cancer Res; 2014 Jan; 20(1):233-45. PubMed ID: 24166903
[TBL] [Abstract][Full Text] [Related]
11. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM
J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201
[TBL] [Abstract][Full Text] [Related]
12. First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.
Li T; LoRusso P; Maitland ML; Ou SH; Bahceci E; Ball HA; Park JW; Yuen G; Tolcher A
J Hematol Oncol; 2016 Mar; 9():23. PubMed ID: 26966027
[TBL] [Abstract][Full Text] [Related]
13. Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.
Macaulay VM; Middleton MR; Eckhardt SG; Rudin CM; Juergens RA; Gedrich R; Gogov S; McCarthy S; Poondru S; Stephens AW; Gadgeel SM
Clin Cancer Res; 2016 Jun; 22(12):2897-907. PubMed ID: 26831715
[TBL] [Abstract][Full Text] [Related]
14. Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase.
Isambert N; Delord JP; Soria JC; Hollebecque A; Gomez-Roca C; Purcea D; Rouits E; Belli R; Fumoleau P
Ann Oncol; 2015 May; 26(5):1005-1011. PubMed ID: 25646368
[TBL] [Abstract][Full Text] [Related]
15. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
Ahn MJ; Kim DW; Cho BC; Kim SW; Lee JS; Ahn JS; Kim TM; Lin CC; Kim HR; John T; Kao S; Goldman JW; Su WC; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; Yang JC
Lancet Respir Med; 2017 Nov; 5(11):891-902. PubMed ID: 29056570
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors.
Jones RL; Kim ES; Nava-Parada P; Alam S; Johnson FM; Stephens AW; Simantov R; Poondru S; Gedrich R; Lippman SM; Kaye SB; Carden CP
Clin Cancer Res; 2015 Feb; 21(4):693-700. PubMed ID: 25208878
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.
Zhao Q; Shentu J; Xu N; Zhou J; Yang G; Yao Y; Tan F; Liu D; Wang Y; Zhou J
Lung Cancer; 2011 Aug; 73(2):195-202. PubMed ID: 21144613
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors.
Kim TM; Lee KW; Oh DY; Lee JS; Im SA; Kim DW; Han SW; Kim YJ; Kim TY; Kim JH; Han H; Kim WH; Bang YJ
Cancer Res Treat; 2018 Jul; 50(3):835-842. PubMed ID: 28859471
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.
Hammond-Thelin LA; Thomas MB; Iwasaki M; Abbruzzese JL; Lassere Y; Meyers CA; Hoff P; de Bono J; Norris J; Matsushita H; Mita A; Rowinsky EK
Invest New Drugs; 2012 Feb; 30(1):316-26. PubMed ID: 20839029
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
